EL-05 · Longevity / EL-06 · Mitochondrial
SS-31
Injection
$649 / month
50 mg · 5 mL vial
EL-06
Mitochondrial
Written by the Elevate Clinical Team
Mitochondrial signaling is an area of active research rather than a single diagnosis. Clinical decisions require attention to the limitations of the evidence and the patient’s overall health.
2 therapies
EL-05 · Longevity / EL-06 · Mitochondrial
MOTS-c
Injection
$549 / month
10 mg/mL · 5 mL vial
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
Clinical considerations
MOTS-c and SS-31 have different evidence bases and regulatory considerations. Neither a mechanistic hypothesis nor laboratory research establishes a promised clinical benefit.
A treatment plan also includes instructions, monitoring and a review of changes in health or medications. Questions about suitability or administration belong with the clinical team.
Written by the Elevate Clinical Team